Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 1295 mL recall — Central Admixture Pharmacy Services, Inc. (Class II)
Central Admixture Pharmacy Services, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 1295 mL — a Class II recall, initiated 2026-06-02 and posted to the FDA enforcement report on 2026-07-01, under recall number D-0618-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Incorrect product formulation: bag did not contain copper and famotidine per label.”. From the product description, the form is injection, the strength given is 1295 mL and it is marked Rx only. Distribution is recorded as “MA” — Limited / regional distribution, with the recalling firm on record in MA, United States. It is the only recall number the FDA has filed under event ID 99265. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0618-2026 |
|---|---|
| FDA event ID | 99265 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Central Admixture Pharmacy Services, Inc. |
| Recall initiated | 2026-06-02 |
| Reported by FDA | 2026-07-01 |
| Report lag | 29 days from initiation to report |
| Distribution | MA — Limited / regional distribution |
| Firm location on record | MA, United States |
| Product description (source) | Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient specific), Rx# 24-1269856-0-1Compound Volume 1295 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admixture Pharmacy Services, Boston, 55 6th Rd Woburn, Massachusetts 01801-1767. |
Reason reported by FDA
Incorrect product formulation: bag did not contain copper and famotidine per label.
12 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
3 identifying values matched by exact pattern in the 36-word product description above; each is a literal substring of it.
| Product named | Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag |
|---|---|
| Form | Injection |
| Strength | 1295 mL |
| Marketing category | Rx only |
Other indexed recalls from Central Admixture Pharmacy Services, Inc.
2 indexed records name Central Admixture Pharmacy Services, Inc. as the recalling firm, across 2 FDA events, reported 2026-07-01 to 2026-08-12. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 416.8 mL | D-0740-2026 | Class III | 416.8 mL · Injection | 2026-08-12 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| MAJOR, 0.2 mg | D-0609-2026 | The Harvard Drug Group LLC | Class II | 2026-07-01 |
| Fenofibrate Capsules, 200 mg | D-0611-2026 | Ajanta Pharma Usa Inc | Class II | 2026-07-01 |
| Corlanor (ivabradine) tablets, 5 mg | D-0612-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Sensipar (cinacalcet) Tablets, 30mg | D-0613-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Sensipar (cinacalcet) Tablets, 60mg | D-0614-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Corlanor (ivabradine) tablets, 7.5mg | D-0615-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Sensipar (cinacalcet) Tablets, 90mg | D-0616-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| DULOXETINE D/R, 30 mg | D-0617-2026 | Direct RX | Class II | 2026-07-01 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-07-01 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| PReye Vitamin See Antioxidant Preservative Free Eye Drops | D-0621-2026 | Preye LLC | Eye Drops | 2026-07-01 |
| BD ChloraPrep Clear, 2% | D-0622-2026 | Carefusion 213, LLC | 2% · Solution | 2026-07-01 |
| BD ChloraPrep FREPP Clear, 2% | D-0623-2026 | Carefusion 213, LLC | 2% · Solution | 2026-07-01 |
| Lacosamide Tablets, 100mg | D-0626-2026 | Annora Pharma Private Ltd | 100mg · Tablets | 2026-07-01 |
| Povi-One, 10% | D-0627-2026 | Elevate Oral Care | 10% | 2026-07-01 |
| Perampanel CIII Tablets, 6mg | D-0628-2026 | Sun Pharmaceutical Industries Inc | 6mg · Tablets | 2026-07-01 |
| Alyacen 7/7/7, 0.5mg/0.035mg | D-0588-2026 | Glenmark Pharmaceuticals Inc., Usa | 0.5mg/0.035mg · Tablets | 2026-06-24 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Central Admixture Pharmacy Services Inc (2 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0618-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0618-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-01
- Ingested
- 2026-08-22
- Record hash
3d12b0e6e77f22b9
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.